52 recruiting, 18 not yet recruiting, 13 active not recruiting, 5 completed. 52 Phase 1, 36 Phase 2, 17 Phase 3, 1 Early Phase 1.
Follow BeOne Medicines: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors BON-106 - Solid Tumor, Advanced Solid Tumor | Phase 1 | Not yet recruiting | BeOne Medicines | 96 | 2026-12-01 | 2026-10-26 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors BG-92505, Anti-Cancer Agent - Advanced Solid Tumor | Phase 1 | Not yet recruiting | BeOne Medicines | 137 | 2026-11-30 | 2026-10-27 |
| A Study of BON-C1393 in Adults With Advanced Solid Tumors BON-C1393, Bevacizumab, Capecitabine - Solid Tumors, Advanced Solid Tumors | Phase 1 | Not yet recruiting | BeOne Medicines | 90 | 2026-11-23 | 2026-10-29 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment Sonrotoclax - Hepatic Impairment, Healthy Adult Participants | Phase 1 | Not yet recruiting | BeOne Medicines | 12 | 2026-11-01 | 2026-10-20 |
| Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden Tislelizumab, Tislelizumab Combined With Chemotherapy, Pembrolizumab - Non-small Cell Lung Cancer Metastatic | Phase 3 | Not yet recruiting | AIO-Studien-gGmbH | 230 | 2026-10-30 | 2026-10-26 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment Tacabrutideg - Hepatic Impairment, Healthy Adult Participants | Phase 1 | Not yet recruiting | BeOne Medicines | 24 | 2026-10-22 | 2026-10-02 |
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 492 | 2026-10-01 | 2026-09-23 |
| A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 BGB-43395, Midazolam, Celecoxib - Healthy Adult Participants | Phase 1 | Recruiting | BeOne Medicines | 24 | 2026-09-25 | 2026-10-23 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-26 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations BG-85738, Tislelizumab, Cetuximab - RAS Mutation, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 100 | 2026-09-02 | 2026-10-23 |
| A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Sonrotoclax - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-09-01 | 2026-09-10 |
| Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy - Mantle Cell Lymphoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 40 | 2026-08-24 | 2026-10-14 |
Showing 20 of 95. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (18) · Lymphoma, Mantle-Cell (10) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Lymphoma, Large B-Cell, Diffuse (5) · Neoplasm Metastasis (5) · Recurrence (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Lymphoma, Non-Hodgkin (4) · Small Cell Lung Carcinoma (4) · Waldenstrom Macroglobulinemia (4) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Esophageal Squamous Cell Carcinoma (3)
zanubrutinib (25) · tislelizumab (20) · obinutuzumab (11) · Rituximab (8) · Drug Therapy (5) · venetoclax (5) · Bendamustine Hydrochloride (4) · Bevacizumab (4) · Capecitabine (4) · Fluorouracil (4) · Fulvestrant (4) · Leucovorin (4) · Oxaliplatin (4) · Letrozole (3) · Specimen Handling (3)
United States (60) · China (55) · Australia (45) · Italy (25) · Spain (24) · South Korea (23) · France (22) · Brazil (21) · New Zealand (21) · Germany (20) · Japan (19) · United Kingdom (19) · Poland (16) · Turkey (Türkiye) (14) · Canada (13)
Akin Atmaca, PD Dr. med. (1) · Alvaro Alencar, MD (1) · Andrew Branagan, MD, PhD (1) · Andrew Zelenetz, MD, PhD (1) · Bei Liu, MD (1) · Diego Villa (1) · Fiyinfolu O Balogun, MD, PhD (1) · Jacob Soumerai, MD (1) · Jennifer A Woyach, MD (1) · Jennifer J. Huang, MD, PhD (1) · Kevin Soares, MD (1)
PMID 32985902, PMID 34826411, PMID 35477432, PMID 36816939, PMID 38502198, PMID 39047732, PMID 39437708, PMID 40465397, PMID 40924923, PMID 42385124
2025 (11), 2023 (7), 2019 (2)